Leishmaniasis pp 359-366 | Cite as

A Novel Method of Vaccination Using Parasite Membrane Antigens

  • James Alexander
  • David G. Russell
Part of the NATO ASI Series book series (NSSA, volume 171)


There have recently been a large number of vaccination studies using mouse models of cutaneous leishmaniasis. These have tended to use either whole attenuated organisms (Howard et al, 1982; Liew et al, 1985) or crude antigen preparations (Liew et al, 1985). Although these vaccine preparations increased resistance if inoculated intravenously (i.v.) or intra-peritoneally (i.p.), they exacerbated infections if administered subcutan-eously (s.c). Intravenous or i.p. vaccination procedures are obviously not acceptable for use with humans. Ideally a vaccine should comprise a purified biochemically defined antigen administered by a cutaneous or intramuscular route without any risk of exacerbating naturally acquired infections. Two antigens have been suggested as potential candidates for successful vaccination, the plasma membrane glycoprotein gp63 and the glycocon-jugate excreted factor (EF). Both antigens are involved in the attachment of the parasite to its host cell, the macrophage (Handman & Goding, 1985; Russell & Wilhelm, 1986), and are found in related forms in all species of Leishmania examined to date (Etges et al, 1985; Colomer-Gould et al, 1985; Handman et al, 1984). We describe here a novel means of presenting these antigens to the immune system and we have successfully vaccinated mice against L.mexicana by the s.c. route.


Cutaneous Leishmaniasis Lesion Diameter Vaccination Procedure Lesion Growth Adoptive Transfer Experiment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Chance, M.L., Schnur, L.F., Thomas, S. C. and Peters, W., 1978, The biochemical and serological taxonomy of Leishmania from the Aethiopian zoogeographical region of Africa, Ann.Trop.Med. and Parasitol., 72:533.Google Scholar
  2. Colomer-Gould, V., Quintas, L. G., Keithly, J. and Noguiera, N., 1985, A common major surface antigen on amastigotes and promastigotes of Leishmania species, J.Exp.Med., 162:902.PubMedCrossRefGoogle Scholar
  3. Etges, R. J., Bouvier, J., Hoffman, R., and Bordier, L., 1985, Evidence that the major surface proteins of three Leishmania species are structurally related, Mol.Biochem.Parasitol., 14:141.PubMedCrossRefGoogle Scholar
  4. Greenblatt, C. H., 1980, The present and future for cutaneous leishmaniasis, in: “New Developments with Human Vaccines”, A. Mizrahi, M. A. Kling-berg and A. Kohn, eds., Alan R. Liss, New York.Google Scholar
  5. Hamaoka, T., and Fujiwara, H., 1987, Phenotypically and functionally distinct T-cell subsets in anti-tumour responses, Immunol.Today 8:267CrossRefGoogle Scholar
  6. Handman, E., and Goding, J. W., 1985, The Leishmania receptor for macrophages is a lipid-containing glycoconjugate, EMBO J., 4:329.PubMedGoogle Scholar
  7. Handman, E., and Mitchell, G. F., 1985, Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis, Proc. Natl. Acad. Sci.USA, 82:5910.PubMedCrossRefGoogle Scholar
  8. Handman, E., Greenblatt, C. H., and Goding, J., 1984, An amphipathic sulphated glycoconjugate of Leishmania characterization with monoclonal antibodies, EMBO J., 3:1206.Google Scholar
  9. Hopp, T. P., 1984, Immunogenicity of a synthetic HBsAg. peptide: enhancement by conjugation to a fatty acid carrier, Mol.Immunol., 21:13.PubMedCrossRefGoogle Scholar
  10. Howard, J. G., Nicklin, S., Hale, C., and Liew, F.Y., 1982, Prophylactic immunization against experimental leishmaniasis: 1. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection, J.Immunol., 129:2206.PubMedGoogle Scholar
  11. Kaye, P. M., 1987, Activation of cell-mediated immunity to Leishmania. 1. Primary T-cell activation detected by IL-2 receptor expression, Immunol., 61:345.Google Scholar
  12. Liew, F. Y., and Dhaliwal, J. S., 1987, Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites, J.Immunol., 138:4450.PubMedGoogle Scholar
  13. Liew, F. Y., Hale, C., and Howard, J. G. 1985, Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection, J.Immunol., 135:2095.PubMedGoogle Scholar
  14. Manson-Bahr, P. E. C., 1961, Immunity in Kala-azar, Trans.R.Soc.Trop.Med.Hyg. 55:550.PubMedCrossRefGoogle Scholar
  15. Mayrink, W., Williams, P., DaCosta, C. A., Magalpaes, P. A., Melr, M. N., Dias, M., Oliveira Lima, A., Michaelick, M. S. M., Ferriera Carvahho, E., Barros, G. C., Sessa, P. A., and De Alencar, J. T. A., 1985, An experimental vaccine against American dermal leishmaniasis: experience in the State of Espirito Santo, Brazil, Ann.Trop.Med. Parasitol., 79:259.PubMedGoogle Scholar
  16. Mitchell, G. F. and Handman, E., 1986, The glycoconjugate derived from a Leishmania receptor for macrophages is a suppressogenic, disease promoting antigen in murine cutaneous leishmaniasis, Parasite Immunol. 8:255.PubMedCrossRefGoogle Scholar
  17. Russell, D. G., and Alexander, J., 1987, Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes, J.Immunol., submitted.Google Scholar
  18. Russell, D. G., and Wilhelm, H., 1986, The involvement of the major surface glycoprotein (gp63) of Leishmania promastigotes in attachment to macrophages, J.Immunol., 136:2613.PubMedGoogle Scholar
  19. Titus, R. G., Ceredig, R., Cerottini, J. C., and Louis, J. A., 1985, Therapeutic effect of anti-L3T4 monoclonal antibody GK 1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice, J.Immunol., 135:2108.PubMedGoogle Scholar
  20. Watari, E., Dietzschold, B., Szohan, G., and Heber-Katy, E., 1987, A synthetic peptide induces long term protection from lethal infection with Herpes simplex virus 2, J.Exp.Med., 165:459.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • James Alexander
    • 1
  • David G. Russell
    • 2
  1. 1.Immunology DivisionUniversity of StrathclydeGlasgowScotland
  2. 2.Department of PathologyNew York University Medical CentreNew YorkUSA

Personalised recommendations